Owners, management and financials
CVR: 25674030
Secondary names: COPYFARM A/S, PILUM PHARMA A/S, Alternova A/S
DKK 2,463,585,000
Revenue
Net result: DKK 77,177,000
ORIFARM GENERICS HOLDING A/S (100%)
CVR · view owners
Thomas Brandhof
Board: Hans Carl Bøgh-Sørensen (chair) and 4 members
CVR · view management
Active
Founded 15 October 2000
CVR · view overview
103 employees
CVR · 2018
Director role ended: Karsten Haumann
CVR · 03/09/2025
View the full event history
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 103 employees (2018). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.
Source: annual report 2025, Danish Business Authority
The financial health of ORIFARM GENERICS A/S appears stable, with a notable increase in revenue from 2.07 billion DKK in 2022 to 2.46 billion DKK in 2025, reflecting a strong upward trend. Profitability has also improved, rising from 54.5 million DKK in 2022 to 77.2 million DKK in 2025, although profit margins have fluctuated. The company's equity position has seen some volatility, decreasing from 554.5 million DKK in 2024 to 496.3 million DKK in 2025, which may raise concerns regarding financial stability. Positioned within the wholesale trade of medical and hospital supplies, ORIFARM GENERICS A/S is a significant player in its industry, demonstrating resilience and growth potential despite some challenges in equity management.
AI-generated summary · Generated 29/05/2026
Selskabets formål er at foretage salg af fortrinsvis generiske lægemidler i Danmark.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 2.5 mia. | 77.2 mio. | 1.3 mia. | 496.3 mio. | 247 | |
| 202401/01/2024 – 31/12/2024 | 2.3 mia. | 59.9 mio. | 1 mia. | 554.5 mio. | 289 | |
| 202301/01/2023 – 31/12/2023 | 2.1 mia. | 62.9 mio. | 1.4 mia. | 494.6 mio. | 289 | |
| 202201/01/2022 – 31/12/2022 | 2.1 mia. | 54.5 mio. | 1.3 mia. | 431.7 mio. | 228 | |
| 202101/01/2021 – 31/12/2021 | 1.8 mia. | 150.1 mio. | 1.2 mia. | 527.3 mio. | 181 | |
| 202001/01/2020 – 31/12/2020 | 688.4 mio. | 145.5 mio. | 455.8 mio. | 201.2 mio. | 117 | |
| 201901/01/2019 – 31/12/2019 | 545 mio. | 103.9 mio. | 330.2 mio. | 145.7 mio. | 99 | |
| 201801/01/2018 – 31/12/2018 | 504.4 mio. | 70.1 mio. | 295 mio. | 116.8 mio. | 102 | |
| 201701/01/2017 – 31/12/2017 | - | 76.4 mio. | 259.7 mio. | 86.8 mio. | 97 | |
| 201601/01/2016 – 31/12/2016 | - | 83.3 mio. | 240.6 mio. | 60.4 mio. | 78 | |
| 201501/01/2015 – 31/12/2015 | - | 605 t. | 46.5 mio. | 8 mio. | - | |
| 201401/01/2014 – 31/12/2014 | - | 550 t. | 31.3 mio. | 7.4 mio. | - | |
| 201301/01/2013 – 31/12/2013 | - | 1.3 mio. | 34.3 mio. | 6.9 mio. | - |
Compared to 293 companies in Engroshandel med læge- og hospitalsartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
22 public tenders won
Showing 10 of 22 contracts
See all won contracts on UdbudsScannerSources: TED (the EU tender database) and udbud.dk
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorThe CVR number of ORIFARM GENERICS A/S is 25674030.
ORIFARM GENERICS A/S is owned by ORIFARM GENERICS HOLDING A/S.
The management of ORIFARM GENERICS A/S consists of Thomas Brandhof.
The board of ORIFARM GENERICS A/S consists of Hans Carl Bøgh-Sørensen, Birgitte Bøgh-Sørensen and Mads Fink Eriksen, with Hans Carl Bøgh-Sørensen as chair.
In 2025, ORIFARM GENERICS A/S reported revenue of DKK 2,463,585,000.
ORIFARM GENERICS A/S had 103 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
ORIFARM GENERICS A/S has published its annual report for 2025. Revenue came to DKK 2,463,585,000, and the net result was DKK 77,177,000.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.12.a" issued by Amgros I/S worth 34,240,300 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.1390.b" issued by Amgros I/S worth 23,945,273 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.1203.a" issued by Amgros I/S worth 368,505,024 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.290.b" issued by Amgros I/S worth 88,050,546 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.1290.b" issued by Amgros I/S worth 13,286,794 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.1210.a" issued by Amgros I/S worth 104,066,115 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.617.b" issued by Amgros I/S worth 43,827,250 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.690.b" issued by Amgros I/S worth 217,081,515 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.790.b" issued by Amgros I/S worth 66,631,361 DKK.
As of October 20, 2025, Nicki Lund Kristensen has joined the board of directors of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.700.a" issued by Amgros I/S worth 245,033,539 DKK.
As of September 3, 2025, Thomas Brandhof is registered as adm. dir. of ORIFARM GENERICS A/S.
As of September 3, 2025, Karsten Haumann has stepped down as adm. dir. of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S has published its annual report for 2024. Revenue came to DKK 2,343,003,000, and the net result was DKK 59,860,000.
As of March 17, 2025, Mads Fink Eriksen has joined the board of directors of ORIFARM GENERICS A/S.
As of March 17, 2025, Erik Sandberg has left the board of directors of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 2.210.a" issued by Amgros I/S worth 36,886,685 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 2.1310.b" issued by Amgros I/S worth 129,999,998 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1391.b" issued by Amgros I/S worth 74,708,177 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.700.a" issued by Amgros I/S worth 313,301,544 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1390.b" issued by Amgros I/S worth 27,640,446 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1290.b" issued by Amgros I/S worth 10,863,807 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1207.b" issued by Amgros I/S worth 9,080,000 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1204.b" issued by Amgros I/S worth 9,670,700 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.1306.b" issued by Amgros I/S worth 18,679,198 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 2.703.b" issued by Amgros I/S worth 183,298,522 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.201.a" issued by Amgros I/S worth 149,993,922 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2025 1.290.b" issued by Amgros I/S worth 4,463,413 DKK.
ORIFARM GENERICS A/S has published its annual report for 2023. Revenue came to DKK 2,137,930,000, and the net result was DKK 62,928,000.
As of January 25, 2024, Thomas Brandhof has joined the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2024, Dennis Dencher has left the board of directors of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S has published its annual report for 2022. Revenue came to DKK 2,074,832,000, and the net result was DKK 54,462,000.
ORIFARM GENERICS A/S has published its annual report for 2021. Revenue came to DKK 1,757,348,000, and the net result was DKK 150,140,000.
As of January 28, 2022, Dennis Dencher has joined the board of directors of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S has published its annual report for 2020. Revenue came to DKK 688,426,000, and the net result was DKK 145,514,000.
ORIFARM GENERICS A/S has published its annual report for 2019. Revenue came to DKK 545,016,000, and the net result was DKK 103,855,000.
ORIFARM GENERICS A/S has published its annual report for 2018. Revenue came to DKK 504,442,000, and the net result was DKK 70,055,000.
ORIFARM GENERICS A/S has published its annual report for 2017. Gross profit came to DKK 171,953,000, and the net result was DKK 76,351,000.
As of May 15, 2018, Karsten Haumann is registered as adm. dir. of ORIFARM GENERICS A/S.
As of May 15, 2018, Ulrik Ernst Rasmussen has stepped down as adm. dir. of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S has published its annual report for 2016. Gross profit came to DKK 169,885,000, and the net result was DKK 83,250,000.
ORIFARM GENERICS A/S has published its annual report for 2015. Gross profit came to DKK 40,010,000, and the net result was DKK 605,000.
ORIFARM GENERICS A/S has published its annual report for 2014. Gross profit came to DKK 32,083,000, and the net result was DKK 550,000.
ORIFARM GENERICS A/S has published its annual report for 2013. Gross profit came to DKK 30,716,000, and the net result was DKK 1,324,000.
As of April 8, 2014, Erik Sandberg has joined the board of directors of ORIFARM GENERICS A/S.
As of April 8, 2014, Hans Christian Eberhard Groth Teisen has left the board of directors of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S has published its annual report for 2012.
As of March 4, 2013, Ulrik Ernst Rasmussen is registered as adm. dir. of ORIFARM GENERICS A/S.
As of March 4, 2013, Erik Sandberg has stepped down as adm. dir. of ORIFARM GENERICS A/S.
As of July 5, 2012, Hans Christian Eberhard Groth Teisen has joined the board of directors of ORIFARM GENERICS A/S.
As of July 5, 2012, Ole Ibsen has left the board of directors of ORIFARM GENERICS A/S.
As of July 5, 2012, Erik Sandberg is registered as adm. dir. of ORIFARM GENERICS A/S.
As of July 5, 2012, Jan Kruse Hansen has stepped down as adm. dir. of ORIFARM GENERICS A/S.
As of October 13, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ORIFARM GENERICS A/S.
As of October 13, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of ORIFARM GENERICS A/S.
As of May 31, 2011, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM GENERICS A/S.
As of May 31, 2011, Birgitte Bøgh-Sørensen has joined the board of directors of ORIFARM GENERICS A/S.
As of March 24, 2009, Ulrik Kronborg Markussen has left the board of directors of ORIFARM GENERICS A/S.
As of March 24, 2009, Jan Kruse Hansen is registered as adm. dir. of ORIFARM GENERICS A/S.
As of March 24, 2009, Hans Carl Bøgh-Sørensen has stepped down as adm. dir. of ORIFARM GENERICS A/S.
As of April 15, 2008, Ole Ibsen has joined the board of directors of ORIFARM GENERICS A/S.
As of April 14, 2008, Per Munk Laustsen has left the board of directors of ORIFARM GENERICS A/S.
As of September 10, 2004, ORIFARM GENERICS HOLDING A/S is registered as an owner of ORIFARM GENERICS A/S with an ownership share of 100%.
As of October 20, 2003, Per Munk Laustsen has joined the board of directors of ORIFARM GENERICS A/S.
As of October 20, 2003, Ulrik Kronborg Markussen has joined the board of directors of ORIFARM GENERICS A/S.
As of October 20, 2003, Ole Michael Friis has left the board of directors of ORIFARM GENERICS A/S.
As of October 20, 2003, Hans Carl Bøgh-Sørensen has left the board of directors of ORIFARM GENERICS A/S.
As of May 31, 2003, Niels Thorborg has left the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2001, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of ORIFARM GENERICS A/S.
As of January 25, 2001, JUT NR. 2180 A/S has stepped down as auditor of ORIFARM GENERICS A/S.
As of January 25, 2001, Ole Michael Friis has joined the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2001, Niels Thorborg has joined the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2001, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2001, Kim Madsen has left the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2001, Peter Andreas Stakemann has left the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2001, Annemette Heller has left the board of directors of ORIFARM GENERICS A/S.
As of January 25, 2001, Hans Carl Bøgh-Sørensen is registered as adm. dir. of ORIFARM GENERICS A/S.
As of January 25, 2001, Peter Andreas Stakemann has stepped down as director of ORIFARM GENERICS A/S.
As of October 15, 2000, JUT NR. 2180 A/S has been appointed auditor of ORIFARM GENERICS A/S.
As of October 15, 2000, Kim Madsen has joined the board of directors of ORIFARM GENERICS A/S.
As of October 15, 2000, Peter Andreas Stakemann has joined the board of directors of ORIFARM GENERICS A/S.
As of October 15, 2000, Annemette Heller has joined the board of directors of ORIFARM GENERICS A/S.
As of October 15, 2000, Peter Andreas Stakemann is registered as director of ORIFARM GENERICS A/S.
ORIFARM GENERICS A/S was founded on October 15, 2000.
Companies in the same industry and area
CVR 17153684
CVR 26058708
CVR 44825775
CVR 46078632
CVR 31312574
